Hepatic glucose production: Typical lean humans spend more than half of their lives in the post-absorptive state, with less than 5 g of glucose circulating in their blood to support life. Many tissues rely on glucose as their primary fuel source. Notable examples are brain, which has limited access to fatty acids, and erythrocytes which do not possess mitochondria and, therefore, rely on glycolysis to meet energy requirements. Even during rest the body uses roughly 8 g of glucose per hour, and during exercise this rate can increase more than twofold. The body would deplete circulating glucose in less than 30 min, resulting in severe hypoglycemia, loss of neurologic function and death, if not for a constant endogenous supply of glucose.

For the first time in many years, the ADA has updated their guidelines on retinopathy. These new guidelines take into account the improvements that have been made in diagnosis and both medical and physical treatments. Most of our colleagues at other medical news outlets either paraphrased the guidelines or printed …

Improvements in assessment and treatment of diabetic retinopathy position statement

This represents the first such update by the American Diabetes Association since 2002, and is notable for inclusion of the latest evidence and recommendations with respect to appropriate eye examination intervals, referral criteria, prevention of incidence and progression of diabetic retinopathy (DR), and treatment strategies.

Should metformin or glyburide, or a combination of both drugs, be the first-line treatment for gestational diabetes?

Is innovative telemedicine the answer to preventing and treating diabetes?

Can patients who use insulin safely fast?

To fast or not to fast.

When asked in a survey, 77% got it wrong! In head-to-head trials of dipeptidyl peptidase 4 (DPP-4) inhibitors vs glucagon-like peptide 1 (GLP-1) receptor agonists, GLP-1 receptor agonists showed more favorable outcomes in all of the following areas except which one? A. Greater glycemic control B. Greater tolerability C. Greater weight loss D. Greater improvement in beta-cell function E. Greater reduction in postprandial triglycerides Were you able to get it right? Follow the link to find out!

Now that a new combination drug of a GLP-1 plus DPP-4 is approved, will you: 1. Recommend it for current patients 2. Wait until we have further information on its use 3. Not sure Follow the link to respond and see what your colleagues think.